Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1994-11-10
1999-08-03
Tsang, Cecilia J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 12, 514 21, 530359, 424450, A61K 3800, C07K 100
Patent
active
059325364
ABSTRACT:
The present invention relates to compositions and methods for neutralizing lipopolysaccharide, and treatment of gram-negative sepsis based therein. Accordingly, the invention is directed to a composition of homogeneous particles comprising phospholipids and a lipid exchange protein, such as phospholipid transfer protein or LPS binding protein. The lipid exchange protein is characterized by being capable of facilitating an exchange protein of lipopolysaccharide into the particles. In a specific embodiment, exemplified herein, the lipid particles are high density lipoprotein particles comprising apolipoprotein A-I (apo A-I), a phospholipid, and cholesterol or a lipid bilayer binding derivative thereof. In a specific example, the phospholipid is phosphatidylcholine (PC). In a specific example, the ratio of phosphatidylcholine:cholesterol:apolipoprotein A-I is approximately 80:4:1. The levels of LPS exchange protein activity in a sample from a patient provides a diagnostic, monitoring, or prognostic indicator for a subject with endotoxemia, gram-negative sepsis, or septic shock.
REFERENCES:
patent: 5128318 (1992-07-01), Levine et al.
patent: 5344822 (1994-09-01), Levine et al.
Fink et al, Journal of Surgical Research, vol. 49, pp. 186-196, 1990.
Cross et al, Infection and Immunity, vol. 61, No. 7, pp. 2741-2747, Jul. 1993.
Bone, Annals of Internal Medicine, vol. 115, No. 6, pp. 457-469, Sep. 15, 1991.
Glauser et al, The Lancet, vol. 338, pp. 732-736, Sep. 21, 1991.
Day et al., 1994, J. Biol. Chem. 269:9388-91.
Hailman et al., 1994, J. Exp. Med. 179:269-77.
van Kessel et al., 1994, J. Immunol. Meth. 172:25-31.
Flegel et al., 1993, Infect. Immunol. 61:5140-46.
Hubsch et al., 1993, Circ. Shock 40:14-23.
Levine et al., 1993, Proc. Natl. Acad. Sci. USA 90:12040-44.
Emancipator et al., 1992, Infect. Immunol. 60:596-601.
Frey et al., 1992, J. Exp. Med. 176: 1665-71.
Wright et al., 1992, J. Exp. Med. 176:719-27.
Shumann et al., 1990, Science 249:1429-31.
Tobias et al., 1989, J. Biol. Chem. 264:10867-71.
Wright et al., 1989, J. Exp. Med. 170:1231-41.
Hesler et al., 1988, J. Biol. Chem. 263:5020-23.
Tobias et al., 1988, J. Biol. Chem. 263:13479-81.
Tollefson et al., 1988, J. Lipid Res. 29:1593-1602.
Tobias et al., 1986, J. Exp. Med. 164:777-93.
Munford et al., 1981, Infect. Immunol. 34:835-43.
Ulevitch et al., 1979, J. Clin. Invest. 64:1516-24.
Ulevitch et al., 1978, J. Clin. Invest. 62:1313-24.
Skarnes et al., 1968, J. Bacteriology 95:2031-34.
Skarnes et al., 1958, J. Exp. Med. 108:685-99.
Rall et al., 1957, Am. J. Physiol. 188:559-62.
Hailman Peter Eric
Wright Samuel D.
Wurfel Mark M.
Mohamed Abdel A.
The Rockefeller University
Tsang Cecilia J.
LandOfFree
Compositions for neutralization of lipopolysaccharides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions for neutralization of lipopolysaccharides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions for neutralization of lipopolysaccharides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-849385